-
Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN), securing exclusive rights to promote the German company’s Stivarga (regorafenib) and Nexavar (sorafenib) in mainland China. Yifan Pharma’s PortfolioYifan Pharma has a team of 300 specialists in oncology marketing and sales. Its product lineup includes…
-
Yifan Pharmaceutical’s Evive Biotech Receives ANVISA Approval for Ryzneuta
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd, has received marketing approval from the Brazil National Health Surveillance Agency (ANVISA) for Ryzneuta (efbemalenograstim alfa, F-627). This approval follows previous marketing nods in China, the United States, and the European Union. Ryzneuta (F-627): A…
-
LG Chem and Yifan Pharmaceutical Launch Hyruan ONE for Knee Osteoarthritis in China
•
LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd (SHE: 002019) from China, have announced the market launch of Hyruan ONE (sodium hyaluronate) in China for the treatment of knee osteoarthritis. Hyruan ONE, originally developed by LG Chem, is a single-dose preparation designed to…
-
Yifan Pharmaceutical’s F-627 Approved by European Commission for Marketing in EU
•
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary Evive Biotech Ltd’s drug Ryzneuta (efbemalenograstim alfa, F-627) has received marketing approval from the European Commission (EC) in the European Union (EU), following a recommendation by the European Medicines Agency’s Committee for Medicinal Products for…
-
Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China
•
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has received marketing approval from the National Medical Products for its generic version of German pharmaceutical giant Bayer’s diazoxide oral suspension. This signifies that the drug has successfully passed the generic quality consistency evaluation (GQCE) process…
-
Yifan Pharmaceutical’s F-652 Shows Promise in Phase II Clinical Trial for ACLF
•
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has reported positive outcomes from a Phase II clinical trial for F-652, a product developed by its subsidiary Evive Biotech Ltd, in the treatment of acute-on-chronic liver failure (ACLF). The trial demonstrated that F-652 not only exhibits good safety and…
-
Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a research partnership with Evive Biotech Ltd, a subsidiary of Chinese pharmaceutical company Yifan Pharmaceutical Co., Ltd (SHE: 002019). The collaboration will utilize Nona’s antibody technology platform, Harbour Mice, to focus on the discovery of dual…
-
Yifan Pharmaceutical’s Subsidiary Receives FDA Approval for Ryzneuta (F-627)
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd., has received Biologic License Application (BLA) approval from the US Food and Drug Administration (FDA) for Ryzneuta (efbemalenograstim alfa, F-627). The drug is indicated to reduce the incidence of infection manifested as febrile neutropenia in…
-
Yifan Pharmaceutical’s F-627 Receives NMPA Approval for Neutropenia Treatment in Cancer Patients
•
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has announced receiving market approval from the National Medical Products Administration (NMPA) for its efbemalenograstim alfa (F-627). This in-house developed long-acting recombinant human granulocyte colony stimulating factor (rhGCSF)-Fc fusion protein is indicated for the prevention and treatment of neutropenia in…
-
Yifan Pharmaceutical Receives NMPA Approval for Hyruan ONE in Knee Osteoarthritis Treatment
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced receiving market approval from the National Medical Products Administration (NMPA) for its in-licensed Category 5.1 drug Hyruan ONE (sodium hyaluronate), which is indicated for use in knee osteoarthritis. Hyruan ONE: A Single-Dose Preparation for Knee OsteoarthritisHyruan ONE, originally developed by LG…
-
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s F-652 has been cleared to start a Phase II clinical trial for a new indication by China’s National Medical Products Administration (NMPA). The trial will assess F-652 as a treatment for alcoholic hepatitis (AH). Mechanism…
-
Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in Germany to its efbemalenograstim alfa (F-627), to Apogepha Arzneimittel GmbH. The German firm will pay Yifan Pharma a USD 400,000 upfront payment, up to USD 1 million development milestone payment, and up to USD 37.5…
-
Yifan Pharmaceutical Licenses F-627 to Acrotech for US Distribution
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the establishment of a licensing agreement with US firm Acrotech Biopharma, Inc., granting the latter exclusive distribution rights to its efbemalenograstim alfa (F-627) in the United States. The drug is an in-house developed long-acting recombinant human granulocyte colony stimulating factor (rhGCSF)-Fc fusion…
